Clinical Guides
Approach to Bleeding Disorders
A safety-first guide to assessing acute and recurrent bleeding, separating platelet, coagulation and mixed disorders, interpreting screening and specialist tests, and coordinating reversal, haemostatic support and referral in India.
MedNext Academy | 14 min read
Approach to Bleeding Disorders
A safety-first guide to assessing acute and recurrent bleeding, separating platelet, coagulation and mixed disorders, interpreting screening and specialist tests, and coordinating reversal, haemostatic support and referral in India.
Summary
Bleeding is first a physiological emergency and only then a diagnostic puzzle. Major external, gastrointestinal, intracranial, retroperitoneal, obstetric or postoperative bleeding requires simultaneous airway and circulation support, haemorrhage control, blood-bank activation, core-temperature and calcium management, and rapid review of antithrombotic medicines. A normal first haemoglobin can coexist with severe acute loss. Do not postpone source control while waiting for a coagulation screen.
For a stable or recurrent presentation, classify the phenotype. Predominantly mucocutaneous bleeding, immediate procedural oozing, petechiae, epistaxis and heavy menstrual bleeding suggest a platelet-number, platelet-function or von Willebrand factor problem. Deep muscle bleeding, haemarthrosis and delayed postoperative bleeding suggest a coagulation-factor defect. These patterns overlap: severe von Willebrand disease can cause deep bleeding, DIC affects platelets and factors, liver disease is mixed, and anticoagulants can produce bleeding at any site. A structured lifetime history is more informative than counting bruises without context.
Start laboratory assessment with a verified complete blood count and film, PT/INR, aPTT and fibrinogen in an appropriate clinical context. Add renal and liver tests, pregnancy testing, haemolysis markers and D-dimer or fibrin-degradation markers when indicated. Normal PT and aPTT do not exclude von Willebrand disease, platelet dysfunction, mild haemophilia or factor XIII deficiency. Mixing studies, von Willebrand assays, factor levels, inhibitor testing, platelet-function studies and ADAMTS13 require correct timing and specialist interpretation. This guide does not provide an individual reversal dose, factor protocol or transfusion order.
How Common Is It?
The frequency of bleeding depends on definition and setting. Easy bruising, epistaxis and heavy periods are common symptoms, while severe inherited factor deficiencies and thrombotic thrombocytopenic purpura are uncommon. Mild inherited disorders are under-recognised because patients and relatives may normalise symptoms and routine screening tests may be normal. Conversely, an abnormal PT, aPTT or platelet count discovered before surgery does not automatically predict clinical bleeding. Population prevalence and laboratory abnormality must be connected to a credible phenotype.
Von Willebrand disease is the most common inherited bleeding disorder, but clinically significant disease is much less frequent than low laboratory values in population studies. Haemophilia A and B are rare, usually X-linked factor deficiencies; symptomatic women and girls occur through several biological mechanisms and should not be dismissed as carriers without bleeding. Acquired bleeding is far more common in hospitals, arising from antithrombotic therapy, liver or kidney disease, sepsis, cancer, obstetric complications, trauma and procedures.
India's burden has distinctive seasonal and access dimensions. Dengue produces large volumes of thrombocytopenia assessment, but platelet count alone does not define severe bleeding or justify prophylactic transfusion. Snake envenomation can cause consumption coagulopathy; obstetric haemorrhage and sepsis can cause DIC; chronic liver disease and anticoagulant use are important mixed causes. Diagnosed case totals for haemophilia and other rare disorders underestimate true need when factor assays, treatment centres and family screening are unevenly available. A useful local audit tracks time to haemostatic treatment, preventable transfusion, delayed diagnosis in women and access to specialist testing rather than relying on one prevalence claim.
Risk Factors
A lifelong pattern, bleeding after circumcision, tooth extraction, tonsillectomy, childbirth or surgery, and similarly affected relatives support an inherited disorder. Ask about both sides of the family and about women with heavy menstrual or postpartum bleeding; an apparently negative family history does not exclude a new mutation, recessive disease or relatives whose symptoms were overlooked. Consanguinity can increase autosomal-recessive platelet or factor disorders but should be discussed respectfully. Blood group, age, pregnancy and physiological stress can influence von Willebrand factor levels and test interpretation.
Acquired risks include aspirin, P2Y12 inhibitors, anticoagulants, non-steroidal anti-inflammatory drugs, selective serotonin-reuptake inhibitors, valproate, some antibiotics, herbal products and alcohol. Record the exact agent, last dose, renal and liver function, indication and concurrent drugs. Heparin exposure raises concern for immune heparin-induced thrombocytopenia, which is primarily thrombotic rather than a simple bleeding disorder. Chronic kidney disease causes qualitative platelet dysfunction; liver disease combines reduced synthesis, thrombocytopenia, dysfibrinogenaemia and altered anticoagulant proteins.
Sepsis, shock, major trauma, placental abruption, amniotic-fluid embolism, retained dead fetus, malignancy, pancreatitis, severe transfusion reaction and some envenomations can trigger DIC. Dengue and other infections may cause thrombocytopenia, capillary leak or organ injury. TTP can be autoimmune or congenital and may be precipitated by pregnancy, infection or other stress. Malignancy, marrow failure and chemotherapy reduce platelet production. Risk is also operational: inability to obtain factor concentrate, fibrinogen, platelet testing, ADAMTS13, urgent imaging, endoscopy or interventional control lowers the threshold for early transfer.
Diagnosis
History
First define site, volume, duration, ongoing loss and symptoms of shock or anaemia. For recurrent bleeding, document epistaxis, gum bleeding, easy bruising, prolonged wounds, heavy menstrual bleeding, postpartum haemorrhage, haemarthrosis, muscle haematoma and delayed bleeding after dental work or surgery. A standardised bleeding assessment tool can structure a stable outpatient history, but it does not replace emergency judgement. Ask about family history, previous haemostatic challenges, transfusions, pregnancies, liver and kidney disease, infection, malignancy, medicines, last anticoagulant dose, supplements and prior laboratory results.
Examination
Repeat pulse, blood pressure, perfusion, respiratory status, mental state and urine output. Identify active source and critical-site symptoms. Petechiae and mucosal oozing support primary-haemostasis failure; tense painful joints, muscle swelling and compartment signs support factor deficiency, but morphology is not absolute. Look for pallor, jaundice, fever, purpura, hepatosplenomegaly, lymphadenopathy, chronic liver signs, renal or neurological injury and thrombosis. In pregnancy assess fetal and obstetric status. Avoid unnecessary rectal, intramuscular or other traumatic procedures in a severely coagulopathic patient.
Investigations
Obtain CBC with smear, PT/INR, aPTT and fibrinogen; add group and screen or crossmatch early in major bleeding. Check renal and liver function, haemolysis markers, pregnancy status and cause-directed tests. Serial platelets, PT, aPTT, fibrinogen and D-dimer help assess evolving DIC. Isolated prolonged aPTT suggests factor VIII, IX, XI or XII deficiency, heparin, lupus anticoagulant or an inhibitor; isolated PT suggests factor VII or vitamin K-related effects; both prolonged suggests multiple-factor, common-pathway or drug effects. Reagent sensitivity matters. A mixing test's immediate and incubated response is interpreted with factor assays and anticoagulant interference. von Willebrand antigen and activity, platelet function, factor levels, inhibitor titres and ADAMTS13 should be obtained and handled according to specialist laboratory protocols.
Differential Diagnosis
Low platelets require confirmation on the film because EDTA clumping, giant platelets or a clotted sample can be misleading. Isolated thrombocytopenia may represent immune thrombocytopenia, dengue, drug effect, gestational thrombocytopenia or hypersplenism. Schistocytes with thrombocytopenia raise thrombotic microangiopathy or DIC; blasts, dysplasia or pancytopenia suggest marrow disease. TTP should be considered with microangiopathic haemolytic anaemia and thrombocytopenia plus variable neurological, cardiac or renal injury. The historical pentad is insensitive and treatment must not wait for all five features.
A platelet-function phenotype with a normal count includes von Willebrand disease, aspirin or other drug effects, uraemia and inherited disorders such as Glanzmann thrombasthenia or Bernard-Soulier syndrome. Normal PT and aPTT are compatible with these diagnoses. Prolonged aPTT with deep bleeding suggests haemophilia A or B, factor XI deficiency or an acquired factor VIII inhibitor; lupus anticoagulant usually predicts thrombosis rather than bleeding unless another abnormality coexists. Factor XII deficiency can markedly prolong aPTT without causing bleeding.
Prolonged PT and aPTT with falling platelets and fibrinogen in a compatible acute illness supports DIC, but serial trends and a validated score are stronger than one panel. Advanced liver disease, massive transfusion, vitamin K deficiency and some anticoagulants can resemble this pattern. Normal screening tests do not exclude factor XIII deficiency. Local structural disease remains important: a single recurrent epistaxis, gastrointestinal bleed, haematuria or postpartum bleed may require ENT, endoscopic, urological or obstetric source investigation even when haemostasis tests are abnormal. The final diagnosis should state bleeding severity, site, phenotype, suspected mechanism, medication effect and unresolved alternatives.
Management
For major bleeding, call the relevant procedural team and blood centre immediately. Apply direct pressure or packing where safe, secure access, resuscitate with warmed products and fluids according to physiology, prevent hypothermia, monitor calcium and acid-base status, and activate the institution's massive-haemorrhage protocol when indicated. Control the source with surgery, endoscopy, interventional radiology or obstetric measures. Component therapy is targeted: red cells restore oxygen carriage; platelets address selected quantitative or qualitative platelet deficits; plasma supplies multiple coagulation factors; cryoprecipitate or fibrinogen concentrate addresses low fibrinogen according to local availability and protocol. Reassess after each intervention.
Temporarily stop an antithrombotic in major bleeding and select reversal from the exact agent, last dose, renal function, laboratory evidence, bleed site and thrombotic indication. Vitamin K and prothrombin-complex concentrate are used in appropriate vitamin K antagonist emergencies; idarucizumab, andexanet or prothrombin-complex strategies have defined direct-oral-anticoagulant roles and access constraints. Do not use a reversal agent routinely for minor bleeding. Plan when to restart anticoagulation because prolonged interruption also causes harm.
Treat the mechanism. Haemophilia with serious suspected bleeding needs immediate factor or haemostatic treatment under the patient's emergency plan, often before imaging. von Willebrand disease may require tranexamic acid, desmopressin after documented suitability, or von Willebrand factor concentrate. DIC management centres on the trigger plus support for bleeding or procedures. Suspected immune TTP requires urgent plasma exchange, corticosteroid-based immunosuppression and specialist consideration of caplacizumab or rituximab; do not wait for a delayed ADAMTS13 result when probability is high. Dengue management follows perfusion, leakage, haematocrit and clinical bleeding rather than chasing the platelet count.
Prescribing Information
Tranexamic acid is useful for many mucosal, dental and menstrual bleeds and in selected major-haemorrhage protocols, but indication, timing, renal adjustment and thrombosis history matter. Avoid casual use in upper urinary-tract bleeding because obstructing clots can form, and do not combine it blindly with activated haemostatic agents. Desmopressin can raise endogenous von Willebrand factor and factor VIII in responsive patients, but response should be known when possible; hyponatraemia, fluid balance, age, cardiovascular disease and tachyphylaxis limit repeated dosing. It does not treat haemophilia B.
Factor VIII, factor IX, von Willebrand factor and bypassing products are prescribed by diagnosis, baseline level, bleed site, pharmacokinetics, inhibitors and target activity. Product names and assay interference matter. Emicizumab is prophylaxis for haemophilia A, not a universal acute factor replacement; it shortens aPTT and makes some aPTT-based assays misleading. Certain bypassing-agent combinations increase thrombosis or thrombotic-microangiopathy risk. Use the treatment centre's written emergency protocol rather than extrapolating a dose from a web table.
For warfarin emergencies, vitamin K provides sustained reversal while four-factor prothrombin-complex concentrate provides rapid factor replacement; plasma is an alternative when concentrate is unavailable but adds volume. Direct oral anticoagulant reversal is agent-specific, and normal PT or aPTT may not exclude clinically relevant factor Xa inhibitor concentrations. Platelet transfusion is not a general antidote for antiplatelet medicines and is not routinely prophylactic in ITP, HIT or TTP. Corticosteroids, immunoglobulin, caplacizumab and rituximab have disease-specific infection, thrombosis, infusion and immunosuppression risks. Pregnancy and paediatric prescribing require specialist protocols.
When to Refer
Refer immediately for haemodynamic instability, uncontrolled bleeding, suspected intracranial, spinal, airway, retroperitoneal or compartment bleeding, major postpartum haemorrhage, haematemesis with compromise, rapidly expanding haematoma or bleeding on an anticoagulant at a critical site. A patient with known haemophilia and significant trauma, head injury, severe headache, neck or throat symptoms, abdominal or iliopsoas pain, or painful joint swelling needs prompt haemostatic treatment and contact with the haemophilia centre. Imaging must not create avoidable treatment delay.
Suspected TTP is a same-day haematology and plasma-exchange emergency. Send an ADAMTS13 sample before plasma treatment if this can be done without delay, calculate clinical probability using an accepted tool where appropriate, and transfer to a centre capable of definitive therapy. DIC with sepsis, obstetric catastrophe, malignancy or trauma requires intensive cause control and serial coagulation support. Severe dengue, shock, organ failure or major bleeding needs an appropriate monitored unit; a platelet count alone is not the transfer diagnosis.
Refer non-emergently but promptly for a high bleeding-assessment score, recurrent procedure-related bleeding, abnormal factor or von Willebrand tests, unexplained prolonged PT or aPTT, suspected platelet dysfunction, acquired inhibitor or inherited disorder. Coordinate heavy menstrual and postpartum bleeding with gynaecology or obstetrics, and plan surgery or dentistry with haematology before the procedure. A referral should include phenotype, family history, prior challenges, exact drugs and last doses, serial CBC and smear, PT, aPTT, fibrinogen, renal and liver results, transfusions, response and any pre-treatment specimens. Confirm an accepting team and transport capability when local factor, plasma exchange or blood components are unavailable.
Red Flags
Physiological red flags are hypotension, narrowing pulse pressure, persistent tachycardia, cool or mottled skin, altered consciousness, oliguria, rising lactate and continued loss. Critical-site warnings include severe or new headache, vomiting, focal deficit, seizure, reduced consciousness, neck swelling, dysphonia, stridor, spinal pain with weakness, tense limb swelling, pain on passive stretch, abdominal distension, flank or groin pain and femoral neuropathy. A stable initial haemoglobin or platelet count does not rule out dangerous bleeding.
Laboratory and syndromic red flags include rapidly falling platelets, new schistocytes, haemolysis, neurological or cardiac injury, acute kidney injury, prolonged PT and aPTT with falling fibrinogen, or failure of expected factor recovery. TTP may present without fever or severe renal failure and should not await the full pentad. DIC evolves over time, so repeat testing when the clinical trigger persists. New thrombocytopenia five to ten days after heparin exposure, especially with thrombosis or skin necrosis, suggests HIT and requires a thrombotic-risk pathway rather than platelet transfusion by reflex.
In dengue, shock, respiratory distress from plasma leakage, severe bleeding, impaired consciousness, hepatitis, myocarditis or other organ dysfunction defines danger; a falling platelet count without clinical deterioration is not equivalent. In pregnancy, placental abruption, postpartum haemorrhage, severe hypertension, fetal compromise and haemolysis with thrombocytopenia require urgent obstetric assessment. Treatment hazards are also red flags: hyponatraemia after desmopressin, thrombosis after reversal or factor products, volume overload from plasma, transfusion reaction, or unexpected assay results during emicizumab or direct oral anticoagulant therapy.
Indian Clinical Context
Indian practice must resist the seasonal platelet-count trap. National and WHO dengue guidance emphasises clinical severity, perfusion, plasma leakage, haematocrit trends, organ involvement and actual bleeding. Prophylactic platelet transfusion for thrombocytopenia alone has not shown benefit in otherwise stable dengue and consumes a limited product. At the same time, shock with falling haematocrit can indicate occult haemorrhage and requires urgent blood and source assessment. Local dengue protocols and current blood-centre policy govern component use.
Snakebite remains an important rural cause of incoagulable blood and bleeding. A properly performed 20-minute whole-blood clotting test can support bedside assessment where recommended, but poor technique, unsuitable glassware and delayed reading can mislead. Antivenom and organ support follow the national snakebite pathway; repeated empirical plasma without controlling venom effect is not definitive treatment. Obstetric DIC, sepsis, trauma, liver disease and anticoagulant-associated bleeding require rapid transfer when surgery, interventional radiology, critical care or components are unavailable.
Access to factor assays, inhibitor testing, platelet aggregometry, ADAMTS13, factor concentrates, bypassing agents and plasma exchange is concentrated in larger centres. A safe district pathway preserves pre-treatment samples, stabilises, contacts the receiving haematology service early and sends serial results rather than waiting for every specialised test. People with haemophilia should carry their diagnosis, inhibitor status, product and emergency plan; women and girls with heavy menstrual or postpartum bleeding deserve the same diagnostic attention. Component scarcity strengthens patient-blood-management principles: treat anaemia, avoid unnecessary phlebotomy and transfusion, use a single therapeutic platelet dose when appropriate, reassess clinically and document antibodies and reactions for future care.
NMC Competency Mapping
The NMC CBME Curriculum 2024 maps this approach most directly to Pathology Topic 20. PA20.1 covers normal haemostasis and the classification, aetiology, pathogenesis and pathology of vascular and platelet disorders, including haemophilia in the curriculum wording. PA20.2 covers DIC and vitamin K deficiency. Blood-bank competencies PA21.1 to PA21.6 add components, grouping, crossmatching, transfusion-transmitted infection and reactions. Physiology and pharmacology supply platelet, coagulation, anticoagulant and haemostatic foundations.
A graduating learner should take a structured personal, menstrual, obstetric, procedural, drug and family bleeding history; distinguish mucocutaneous from deep bleeding without treating the distinction as absolute; and recognise haemodynamic and critical-site emergencies. They should interpret CBC and film, PT, aPTT and fibrinogen as screening tests, explain why normal results do not exclude all disorders, and state when mixing studies, von Willebrand tests, factor assays, platelet-function studies or ADAMTS13 are needed.
Integrated assessment can use a child with haemarthrosis, a woman with heavy menstrual and postpartum bleeding, an adult with acquired factor inhibitor, sepsis with evolving DIC, anticoagulant-associated gastrointestinal bleeding, dengue with thrombocytopenia or TTP with schistocytes. The learner should stabilise, preserve key samples, formulate differentials, select first tests and arrange appropriate referral. Undergraduate competence does not authorise unsupervised factor dosing, anticoagulant reversal, plasma exchange, platelet-function interpretation or transfusion. Examinees should explicitly separate clinical urgency from the time required for definitive classification.
Key Exam Pearls for NEET PG
Primary-haemostasis disorders classically cause petechiae, purpura, epistaxis, gum bleeding, heavy menstrual bleeding and immediate oozing. Secondary-haemostasis disorders cause delayed bleeding, haemarthrosis and muscle haematoma. Remember the overlap: severe von Willebrand disease can lower factor VIII and cause deep bleeding, while DIC and liver disease are mixed disorders. A normal platelet count does not prove normal platelet function. Bleeding time is poorly reproducible and is not a modern routine screening test.
An isolated prolonged aPTT suggests intrinsic-factor deficiency, heparin, lupus anticoagulant or a specific inhibitor. Immediate correction on mixing supports deficiency; time-dependent failure suggests an inhibitor, but anticoagulants and assay design complicate the result. Factor XII deficiency prolongs aPTT without bleeding. Isolated prolonged PT points toward factor VII, vitamin K antagonist effect or early multiple-factor deficiency. Both prolonged with thrombocytopenia, raised fibrin markers and falling fibrinogen in a compatible trigger supports DIC. Serial change matters.
Haemophilia A is factor VIII deficiency and haemophilia B factor IX deficiency. von Willebrand factor carries factor VIII. Desmopressin can help selected responsive von Willebrand disease and mild haemophilia A, not haemophilia B. TTP is thrombocytopenia plus microangiopathic haemolytic anaemia with variable organ injury; do not wait for the pentad or ADAMTS13 result before high-probability treatment. Platelet transfusion can worsen thrombosis and is generally avoided unless bleeding is life-threatening.
In anticoagulant bleeding, identify the exact drug and last dose; PT and aPTT may not exclude a factor Xa inhibitor. In dengue, treat the patient, perfusion and leakage rather than the count. For NMC anchor the mechanism to PA20.1, DIC and vitamin K deficiency to PA20.2, and component safety to PA21.
Frequently Asked Questions
Can normal PT and aPTT rule out a clinically important bleeding disorder?
No. von Willebrand disease, qualitative platelet disorders, mild factor deficiencies and factor XIII deficiency may have normal routine screening times. A convincing personal or family bleeding history still warrants specialist-directed testing. PT and aPTT are also reagent-dependent and can be altered by anticoagulants without predicting the exact in-vivo bleeding risk.
How should a mixing study be interpreted in a patient with prolonged aPTT?
Correction after mixing patient plasma with normal plasma supports a factor deficiency, while non-correction suggests an inhibitor or anticoagulant effect. However, some inhibitors are time- and temperature-dependent, and direct oral anticoagulants or heparin can distort results. Interpret immediate and incubated studies with medication history, thrombin or anti-Xa testing where available, and specific factor and inhibitor assays.
Should every very low platelet count in dengue receive platelet transfusion?
No. Current dengue care evaluates perfusion, plasma leakage, haematocrit trend, organ involvement and clinical bleeding. Prophylactic platelet transfusion for a low count alone in an otherwise stable patient has not shown benefit and uses a scarce component. Major bleeding, a critical-site procedure or another haemostatic disorder requires individual blood-bank and specialist assessment under the current local protocol.
What makes suspected thrombotic thrombocytopenic purpura an emergency?
Immune TTP can cause rapidly fatal microvascular thrombosis affecting brain, heart and other organs. Thrombocytopenia with microangiopathic haemolytic anaemia is enough to trigger urgent probability assessment; the old five-feature pentad is not required. Draw ADAMTS13 before plasma if this causes no delay, contact a plasma-exchange centre immediately, and begin high-probability treatment under specialist direction while confirmation is pending.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic